Home › Trials › Lung

Lung cancer

A Study Comparing Low-Dose and Standard-Dose Lorlatinib with Posaconazole in Patients with ALK gene-Positive Advanced Lung Cancer (A Low-Cost Initiative)

Who can joinAdults

Age18+ years

Kind of studyStudy of how care is given

What it testsA medicine

The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.

Contact hospital

The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.

Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)Navi Mumbai, MaharashtraDirections ↗

Registry summary (technical)

An Open-Label, Sequential Pharmacokinetic and Safety Evaluation of Standard Dose Lorlatinib (100 mg daily) versus Low Dose Lorlatinib (25 mg daily) in Combination with Oral Posaconazole (300 mg daily) In Patients with ALK-Positive Advanced Non Small Cell Lung Cancer: A Low-Cost Initiative. (LOWLORP) - LOWLORP

Sponsor: ACTREC, TMC Tata Memorial Centre
CTRI/2026/02/104994 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 30 Mar 2026 · read by us 5 Nov 2026

Need help reaching the trial team? Write to us.

Tell us the city, the type of cancer and the trial number if you have one. We reply in simple words within 3 working days.

ट्रायल टीम से जुड़ने में मदद चाहिए? हमें ईमेल करें।

ట్రయల్ టీమ్‌ను సంప్రదించడానికి సహాయం కావాలా? మాకు ఈమెయిల్ చేయండి.

சோதனைக் குழுவை தொடர்பு கொள்ள உதவி வேண்டுமா? எங்களுக்கு மின்னஞ்சல் செய்யுங்கள்.